Key Details
Price
$20.34Annual EPS
-$1.08Annual ROE
44.93%Beta
0.75Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Screeners with MBX included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of the last subject's last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the Company's long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist in development for the treatment of post-bariatric hypoglycemia (PBH).
CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its management team will participate in the following upcoming investor conferences:
CARMEL, Ind., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that both the rationale and design of the Phase 2 Avail™ trial of MBX 2109, the Company's potential long-acting parathyroid hormone (PTH) peptide prodrug, in adults with hypoparathyroidism (HP) were featured in a poster presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting held in Toronto, ON, Canada September 27-30, 2024.
CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the closing of its previously announced upsized initial public offering of 11,730,000 of its common stock at a price to the public of $16.00 per share, which includes 1,530,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The aggregate gross proceeds to MBX Biosciences from the offering were approximately $187.7 million, before deducting underwriting discounts and commissions and offering expenses.
FAQ
- What is the primary business of MBX Biosciences Common Stock?
- What is the ticker symbol for MBX Biosciences Common Stock?
- Does MBX Biosciences Common Stock pay dividends?
- What sector is MBX Biosciences Common Stock in?
- What industry is MBX Biosciences Common Stock in?
- What country is MBX Biosciences Common Stock based in?
- When did MBX Biosciences Common Stock go public?
- Is MBX Biosciences Common Stock in the S&P 500?
- Is MBX Biosciences Common Stock in the NASDAQ 100?
- Is MBX Biosciences Common Stock in the Dow Jones?
- When was MBX Biosciences Common Stock's last earnings report?
- When does MBX Biosciences Common Stock report earnings?
- Should I buy MBX Biosciences Common Stock stock now?